Trials / Completed
CompletedNCT00730223
Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Vanderbilt University · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To see if certain variations in the CYP2B6 gene contribute to differences in plasma drug levels and central nervous system side affects in people who take nevirapine or efavirenz.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nevirapine and Efavirenz | single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2006-03-01
- Completion
- 2009-08-01
- First posted
- 2008-08-08
- Last updated
- 2013-02-15
Source: ClinicalTrials.gov record NCT00730223. Inclusion in this directory is not an endorsement.